Story can be found in FierceBiotech news. AZN acquired one private ADC company Spirogen and struck a licensing deal with another. Seems there are more players entering the industry with new technologies. IMGN better run fast to the finish line!
Paragraph pasted from the FB report: "Through the buyout, MedImmune gets Spirogen's proprietary pyrrolobenzodiazepine (PBD) technology, DNA binding agents that can ferret out cancer cells and delivery targeted cytotoxic payloads, CEO Chris Martin told FierceBiotech. Spirogen's technology is orders of magnitude more potent than first-generation ADCs, Martin said, allowing the agents to maintain their effectiveness in resistant cells."
I'm thinking IMGN scientists must be great with the DC part but not in picking the A part, or targets for the A part. There are so many surface proteins, and yet they can't seem to find one in a cancer sweet spot.
Yeah, well part of the problem is that not all receptors are internalized. if herceptin was working because of adcc, when you add a cytotoxic bomb you then are counting on the her2 receptor being internalized and the bomb being taken up and it's a gamble as to which ones will be internalized.
I think they are getting better and will have some winners from the 10 drugs in development. Maybe not all will work, they just need one wholly-owned drug to work (PCYC has just one that's jointly owned and is up 10X in 24 months). I think 289 is going to be great, "the one" that gets everything right. They have great partners like NVS, AMGN, LLY to pick the right A and target (clown is getting excited, mind is swirling). Bayer and Sanofi are also good companies, maybe not as strong as Roche, NVS and AMGN, but had some success in Oncology. LLY is hard to figure, lots of failures, but they own Erbitux for which they paid a fortune. I am hoping that's the A to which IMGN is attaching their DC (clown is getting excited again).